cysteamine

(redirected from Procysbi)
Also found in: Dictionary.

cysteamine

 [sis-te´ah-mēn″]
a sulfhydryl amine that is part of coenzyme A; it reduces intracellular cystine levels and is used in treatment of nephropathic cystinosis; administered orally.

cys·te·a·mine

(sis-tā'a-mēn),
2-Aminoethanethiol; a sulfhydryl compound used experimentally to produce ulcers in rats and as a radioprotective agent; antidote to acetaminophen.

cysteamine

[siste′ämēn′]
a sulfhydryl amine that is part of coenzyme A. It reduces intracellular cystine levels and is used in treatment of nephropathic cystinosis. It is administered orally.

cysteamine

A stable aminothiol and metabolite of the amino acid cysteine.

Physiologic role
Cysteamine forms coenzyme A by combining with pantothenate and adenosine triphosphate.

Potential therapeutic role
Cysteamine has been in clinical trials for managing Batten disease, cystinosis, non-alcoholic steatohepatitis and Huntington's disease.

cysteamine

Mercaptamine, a drug used to treat NEPHROPATHIC CYSTINOSIS and prescribable only by urological specialists. A brand name is Cystagon.
References in periodicals archive ?
Procysbi is the first cystine-depleting agent given every 12 hours that is approved in the United States for the treatment of nephropathic cystinosis, a rare metabolic disorder, in adults and children 2 years of age and older.
Biopharmaceutical company Raptor Pharmaceutical Corp (Nasdaq:RPTP) announced on Thursday the approval by the European Commission (EC) of PROCYSBI gastro-resistant hard capsules of cysteamine (as mercaptamine bitartrate), as an orphan medicinal product for the treatment of proven nephropathic cystinosis for marketing in the European Union (EU).
Following the Raptor acquisition at the end of last year, we completed an evaluation of the commercial infrastructure required to provide PROCYSBI and QUINSAIR in Europe, the Middle East and Africa, and determined that these medicines would be best supported by a company with a larger geographic footprint, said Timothy P Walbert, chairman, president and chief executive officer of Horizon Pharma, in a news release.
Biopharmaceutical company Raptor Pharmaceutical Corp (NasdaqGM:RPTP) reported on Thursday the receipt of marketing approval from the European Commission (EC) for PROCYSBI for the treatment of proven nephropathic cystinosis EC in the European Union (EU).
Raptor's previously disclosed total net sales guidance for full-year 2016 is $125 million to $135 million, which includes both PROCYSBI and QUINSAIR.
M2 PHARMA-June 26, 2013-Raptor Pharmaceutical Corp awarded US orphan drug exclusivity for PROCYSBI for nephropathic cystinosis(C)2013 M2 COMMUNICATIONS
M2 EQUITYBITES-June 26, 2013-Raptor Pharmaceutical Corp awarded US orphan drug exclusivity for PROCYSBI for nephropathic cystinosis(C)2013 M2 COMMUNICATIONS http://www.
M2 PHARMA-June 24, 2013-Raptor Pharmaceutical introduces Procysbi in US(C)2013 M2 COMMUNICATIONS
Raptor is leading the global commercialization of two products for orphan diseases, including PROCYSBI, for the management of nephropathic cystinosis in adults and children ages two years and older, and QUINSAIR, an inhaled fluoroquinolone antibiotic for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis (CF).
M2 EQUITYBITES-June 24, 2013-Raptor Pharmaceutical introduces Procysbi in US(C)2013 M2 COMMUNICATIONS http://www.
M2 PHARMA-May 2, 2013-Raptor's PROCYSBI approved by US FDA for treatment of Nephropathic Cystinosis(C)2013 M2 COMMUNICATIONS